NYSEMKT:CANF
Can-Fite BioPharma Ltd Stock News
$1.94
-0.0300 (-1.52%)
At Close: Apr 24, 2024
CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS
11:06am, Thursday, 03'rd Jun 2021
Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In addition, NASH is expected t
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
07:35am, Wednesday, 02'nd Jun 2021
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
07:00am, Wednesday, 02'nd Jun 2021
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
06:00am, Thursday, 27'th May 2021
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES
09:30am, Wednesday, 12'th May 2021
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced the
Can-Fite Expands Mid-Stage COVID-19 Study To Europe
08:07am, Thursday, 22'nd Apr 2021
Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized, double-blind, placebo-controlled study
Can-Fite Expands its Phase II COVID-19 Study to Europe
07:20am, Thursday, 22'nd Apr 2021
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres
Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing
11:18am, Tuesday, 20'th Apr 2021
Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for its drug candidates Piclidenoson and Na
New Strong Sell Stocks for April 19th
11:39am, Monday, 19'th Apr 2021
PAC, CANF, GOL, HRTH, and INLX have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2021
Can-Fite Says Cannabinoid-Based Therapies Stop Liver Cancer Growth, Preclinical Studies Show
11:46am, Monday, 05'th Apr 2021
Can-Fite BioPharma (NYSE: CANF) has completed pre-clinical studies demonstrating that a Cannabidiol (CBD)-rich T3/C15 cannabis fraction induces inhibition of liver cancer cell growth. The company'
Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
07:00am, Friday, 19'th Mar 2021
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
CANF Stock Price Increases Over 15% Pre-Market: Why It Happened
07:45am, Thursday, 18'th Mar 2021
The stock price of Can Fite Biopharma (NYSE American: CANF) has increased by over 15% pre-market. This is why it happened.
Why Can-Fite, Moderna, AC Immune Shares Are Rallying
10:52am, Tuesday, 16'th Mar 2021
Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.
CANF Stock: Why Are Can-Fite Biopharma Shares Skyrocketing Today?
10:16am, Tuesday, 16'th Mar 2021
Can-Fite Biopharma (CANF) stock is on the rise Tuesday after announcing a $42.7 million distribution rights deal with Ewopharma. The post CANF Stock: Why Are Can-Fite Biopharma Shares Skyrocketing Tod
CanFite Biopharma Ltd (CANF) Upgraded to Buy: Here's Why
12:56pm, Friday, 05'th Mar 2021
CanFite Biopharma Ltd (CANF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
